N/A N=88 Randomized Single-blind Treatment

Cognitive-Behavioral Therapy in Veterans With Schizophrenia

Schizophrenia · Schizoaffective Disorder

Bottom Line

View on ClinicalTrials.gov: NCT00688259 ↗

Enrolled (actual)

Serious AEs

26.1%

Results posted

Dec 2017

Primary outcome: Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Supportive Therapy (ST) (Behavioral); Cognitive Behavioral Therapy for Psychosis (CBTp) (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: VA Office of Research and Development
Primary completion: Sep 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Changes in Positive Schizophrenia Symptoms	3.21; 3.30; 3.12; 2.78	.09
PRIMARY Changes in Positive Schizophrenia Symptoms	3.21; 3.30; 3.12; 2.78	.09
PRIMARY Changes in Global Social Functioning	5.00; 4.80; 4.63; 4.56	.55
PRIMARY Changes in Global Social Functioning	5.00; 4.80; 4.63; 4.56	.55
SECONDARY Changes in Distress From Schizophrenia Symptoms	40.79; 40.70; 35.43; 31.48	.25
SECONDARY Changes in Distress From Schizophrenia Symptoms	40.79; 40.70; 35.43; 31.48	.25

Summary

This is a study comparing the benefits of two types of individual psychotherapy (cognitive-behavioral therapy for psychosis and supportive therapy) in symptomatic Veteran outpatients diagnosed with schizophrenia or schizoaffective disorder. Treatment lasted approximately 6 months, with outcome data on symptoms, functioning, and distress levels collected at baseline, post-treatment, and 6 months post -treatment follow-up.

Eligibility Criteria

Inclusion Criteria

outpatients with schizophrenia or schizoaffective disorder in proximity to the West Los Angeles VAMC
at least one month since last hospitalization
stable antipsychotic medication with persisting psychotic symptoms with at least minimal distress
competent to sign informed consent.

Exclusion Criteria

in other individual psychotherapy
presence of organic brain disease
mental retardation
illness that would prohibit regular attendance in therapy
substance dependence diagnosis in the past 6 months.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00688259). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.